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Background: Development of interventions that address psychosocial and existential distress in people with
motor neurone disease (MND) or that alleviate caregiver burden in MND family carers have often been suggested
in the research literature. Dignity therapy, which was developed to reduce psychosocial and existential distress
at the end of life, has been shown to benefit people dying of cancer and their families. These results may not be
transferable to people with MND. The objectives of this study are to assess the feasibility, acceptability and potential
effectiveness of dignity therapy to enhance the end of life experience for people with motor neurone disease
and their family carers.
Methods/design: This is a cross-sectional study utilizing a single treatment group and a pre/post test design.
The study population will comprise fifty people diagnosed with MND and their nominated family carers. Primarily
quantitative outcomes will be gathered through measures assessed at baseline and at approximately one week
after the intervention. Outcomes for participants include hopefulness, spirituality and dignity. Outcomes for family
carers include perceived caregiver burden, hopefulness and anxiety/depression. Feedback and satisfaction with
the intervention will be gathered through a questionnaire.
Discussion: This detailed research will explore if dignity therapy has the potential to enhance the end of life
experience for people with MND and their family carers, and fill a gap for professionals who are called on to
address the spiritual, existential and psychosocial needs of their MND patients and families.
Trial registration: ACTRN Trial Number: ACTRN12611000410954
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Dignity therapyBackground
As a result of elevated interest in hastened death at the
end of life by people with motor neurone disease
(MND), also known as amyotrophic lateral sclerosis
(ALS), numerous studies have examined factors that
affect quality of life, psychological health, and end-of-life
distress in this population. Findings indicate that quality
of life in MND-diagnosed individuals is independent of
physical decline [1,2]; that interest in hastened death
is correlated with hopelessness [3,4]; and that MND* Correspondence: brenda.bentley@curtin.edu.au
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reproduction in any medium, provided the orpatients with higher levels of spirituality and sense of
meaning experience less end of life distress [5,6]. This
research has resulted in a call to develop psychosocial
interventions for use with the MND population that
will bolster hopefulness, spirituality, and meaning [7,8];
however, very little work has been done to develop and
implement such interventions.
MND is a family disease, and family carers carry an
exceptional burden by providing a high level of care,
often for the duration of the illness. Family carers of
people with MND are more depressed than people with
MND overall [9]. As time goes on and dependency
increases, family carers exhibit increasing levels of dis-
tress symptoms [10,11]. Studies on the quality of life inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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burden can be alleviated by finding positive meaning
[12,13] and by supporting a sense of hope [14].
Dignity therapy, a brief psychotherapeutic intervention
based on empirical research into the concept of dignity
at the end of life [15], has proven successful at increas-
ing hope, sense of meaning and will to live in a palliative
care population, where most patients had cancer diagno-
ses. Dignity therapy offers people with terminal illness
the opportunity to create a generativity document. In a
recorded interview guided by a counsellor or health care
professional, the participant is invited to recount aspects
of their life they want remembered, find meaning and
purpose to their life, and express final words or advice.
The interview is transcribed and edited, and a final dig-
nity therapy transcript is returned to the participant to
share with others as they wish.
A pilot study of dignity therapy produced positive
results for participants and family members. A heigh-
tened sense of dignity was reported in 76% of partici-
pants, an increased sense of purpose was reported by
68%, an increased sense of meaning was reported by
67%, and 47% reported an increased will to live [16].
A recent randomised controlled trial reported similar
outcomes [17]. In the pilot study, family members were
also positive about the intervention, with 95% reporting
they would recommend dignity therapy, 78% reporting
that it helped them during their time of grief, and 77%
believing the document would be a continuing source
of comfort [18].
Nonetheless, because these studies both utilized a pri-
marily cancer population, the results are not transferable
to people with MND. Ability to communicate, cognitive
acuity, stage of illness, baseline levels of distress and
demographic features are some of the factors that may
vary in this population and make implementation of dig-
nity therapy difficult. The delivery of the intervention
may require modification, i.e. to be performed at an earl-
ier stage in the disease process or by utilizing assisted
communication methods. Therefore, feasibility testing of
dignity therapy with the MND population is warranted
[19,20].
Moreover, while the previous dignity therapy study
focused on the intervention’s positive influence on the
bereavement experience of family members, it did not
look at how the intervention may affect the carer during
the caring experience.
Aims and objectives
The aims of this study are to assess the feasibility,
acceptability and potential effectiveness of dignity ther-
apy to enhance the end of life experience for people with
MND and their family carers. The specific objectives
are to:a) Determine whether dignity therapy is likely to
increase hope, meaning and dignity in people
with MND.
b)Determine whether dignity therapy is likely to
increase hope, and decrease anxiety, depression,
and perceived burden in family carers of people
with MND.
c) Determine whether dignity therapy is acceptable
to people with MND and their family carers.
d)Determine whether it is feasible to provide dignity
therapy to people with MND.
e) Pilot methods for a future randomized controlled
trial.
Methods
Study design
This is a cross-sectional study utilizing a single treat-
ment group and a repeated measures pre/post test
design. A control group is not being utilized due to
1) the small MND population available in Western Aus-
tralia 2) access issues to people with MND, and 3) the
fact that dignity therapy (nor any other psychosocial
intervention) has yet to be tried with this palliative care
population and the feasibility of dignity therapy needs to
be tested before proceeding to an RCT. The study design
has been modelled to reduce bias and increase validity
where possible. For example, the short duration of the
intervention coupled with utilizing a single post-testing
point one week after the intervention will minimize con-
founding variables.
Ethical approval
This study has been approved by the Curtin University
Human Research Ethics Committee (19/2011).
Participants
The sample will comprise 50 adults diagnosed with
MND who are registered with the MND Association of
Western Australia. A second group will consist of up to
50 family carers of the participants.
People with MND
Inclusion criteria Persons with a diagnosis of MND
aged 18 and over who are able to communicate in Eng-
lish are included in the study. As this is a feasibility
study, participants who are unable to communicate ver-
bally may participate if they are able to utilize an assisted
communication method. Communication issues will be
explored and reported in the findings. There is no selec-
tion criteria based on stage of the disease as MND is a
fatal disease with no hope of remission making an end-
of-life intervention appropriate at any time after diagno-
sis. Participants will not be screened for existential or
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at baseline.
Exclusion criteria Participants who are unable to provide
informed consent, either due to cognitive issues or illness
severity will be excluded. Cognitive impairment will be
screened using the ALS-Cognitive Behavioral Screen [36].
If the participant receives a score of less than ten, the par-
ticipant and family carer will be excluded from the study.
Family carers
A family carer of each participant will be invited to take
part in the study, comprising a second research popula-
tion of up to 50 family carers. A family carer is defined
as the person indicated by the participant as the primary
family carer. The family carer must be at least 18 years
of age, able to provide informed consent and able to
communicate in English. If the family carer does not
wish to participate, then the person with MND remains
eligible to take part in the study.
The intervention and study procedures
The intervention will be administered by the researcher, a
counselling psychologist undertaking a PhD by research
at Curtin University in Western Australia. The researcher
has been trained in dignity therapy at an intensive work-
shop by Professor Harvey Chochinov, who developed the
intervention and who performed the empirical studies
upon which the intervention is based.
Recruitment will be undertaken through the MND Asso-
ciation of Western Australia (MNDAWA). MNDAWA will
liaise directly with participants to protect the identity of
MND-diagnosed individuals. Letters will be sent out to all
members of MNDAWA and potential participants are
identified when they telephone the researcher or return a
copy of the letter expressing their interest. The researcher
will first speak with the person with MND or family carer
to elaborate further on the nature of the study and answer
any questions. If the participant wishes to proceed, a
meeting will be scheduled. If time permits, information
sheets and consent forms will be mailed in advance of
the meeting to provide time to consider the study and
discuss their participation with family and health care
providers. All meetings will occur at a time of the parti-
cipant’s choosing and in their care environment. Since
the participant’s condition can fluctuate, the timing of
the contacts can be flexible and meetings rescheduled.
The researcher will make detailed notes of these experi-
ences in order to include information about timing issues
in the findings.
At the initial meeting, the researcher will review the
participant and family carer information and consent
forms with the participant/family carer dyad, check for
understanding and answer any outstanding questions.Written consent will be obtained and MND participants
will be tested for cognitive impairment that is significant
enough to exclude them from the study. If the participant
and family carer remain in the study, socio-demographic
and health questionnaires and baseline measures will be
collected from each. An appointment for the first dignity
therapy session will be made, ideally within two to three
days. The researcher will provide the participant a copy of
the dignity therapy question framework so that they may
begin reflecting on their responses.
Dignity therapy question protocol
Tell me a little about your life history; particularly the
parts that you either remember most or think are the
most important? When did you feel most alive?
Are there specific things that you would want your
family to know about you, and are there particular
things you would want them to remember?
What are the most important roles you have played in
life (family roles, vocational roles, community service
roles, etc.)? Why were they so important to you, and
what do you think you accomplished in those roles?
What are your most important accomplishments, and
what do you feel most proud of?
Are there particular things you feel still need to be said
to your loved ones or things that you would want to
take time to say once again?
What are your hopes and dreams for your loved ones?
What have you learned about life that you would want
to pass along to others? What advice or words of
guidance would you wish to pass along to your son,
daughter, husband, wife, parents, other(s)?
Are there words or perhaps even instructions that you
would like to offer your family to help prepare them for
the future?
In creating this permanent record are there other thing
you would like included?
[16] at p. 5522.
The next meeting is the primary dignity therapy ses-
sion, where participants are invited to address and rec-
ord themes, thoughts and feelings about themselves and
their lives that they would like remembered. The ques-
tion framework is flexible, and provides a guide for the
researcher to shape the interview by following the parti-
cipant’s cues. If the participant desires, a family carer
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tional support and help facilitate the interview. If partici-
pants require a second or third interview session due to
communication issues, fatigue, or the breadth of infor-
mation they would like to share, these will be scheduled
as soon as possible.
After recording has finished, a verbatim transcript
will be prepared (usually within 24–48 hours). The
researcher will shape the interview into a narrative using
the learned dignity therapy editing method, which omits
non-starters and irrelevant sections (such as interrup-
tions) and tags content that needs to be clarified or
perhaps omitted due to the harm it could inflict on reci-
pients. Another appointment will be made with the par-
ticipant as soon as practicable to read through and edit
the transcript. In this session, the participant will be
invited to make corrections, clarifications or additions as
desired. In the final dignity therapy session, the final
bound transcript is given to the participant. The partici-
pants may have as many copies of the document as they
wish and share them with whoever they choose.
Post-testing will occur with both the participant and fam-
ily carer one week after the final dignity therapy document
has been returned. To reduce response bias, post-testing
questionnaires will be sent out and returned via mail. A re-
search officer (not related to the project) from the Western
Australian Centre for Cancer and Palliative care will per-
form the post-testing if assistance is needed to complete
the questionnaires. A single point of post-testing soon after
completion of the sessions is planned in order to reduce
moderating variables. Further, the possible immediate im-
pact of the intervention is being examined for the purposes
of this feasibility study and not the longevity of the out-
comes, which can be assessed in future studies. A study
design flow chart is shown in Figure 1.Measures and outcomes
The measures chosen have been validated and are quick
and easy to administer and use, in order to decrease the
burden on the study population. Brief versions of the
outcome measures have been selected where available.Primary outcome measure for people with MND
The primary outcome measure is the participant’s sense
of hopefulness. This will be assessed utilizing the Herth
Hope Index [21,22], a validated instrument developed
for use with the terminally ill. Distressed MND patients
score higher on hopelessness than distressed cancer
patients at the end of life [23], and interest in hastened
death or suicidal ideation in the MND population has
been shown to correlate with hopelessness [3,24], which
indicates that the level of hopefulness a key factor of
psychological distress in this disease population.Secondary outcome measures for people with MND
Secondary outcome measures used to assess potential
effectiveness include, 1) dignity, which will be measured
with the Patient Dignity Inventory (PDI) [25], a validated
measure which evolved directly from the empirical
studies into dignity concerns in the terminally ill, and;
2) spiritual well-being, which will be measured with the
Functional Assessment of Chronic Illness Therapy-
Spiritual Well-Being Scale (FACIT-sp-12) [26], a vali-
dated measure showing strong internal reliability. To
assess the acceptability of dignity therapy, a modified
version of the dignity therapy Patient Feedback Ques-
tionnaire [17] is being utilized to collect information on
the views, experiences and opinions of the participants
about the intervention. To assess the feasibility of the
intervention, data will be collected about the time taken
to organize and conduct the dignity therapy sessions,
any special accommodations made in the delivery of the
intervention, deviations from the dignity therapy proto-
col, and reasons for non-completion. The researcher will
also record, through the use of a journal, observations
and experiences of delivering the intervention, including
positive and negative participant responses.Primary outcome measure for family carers
The primary outcome is the family carer’s sense of per-
ceived burden, which will be measured through the Zarit
Burden Inventory [27]. Research of caregiver burden
in MND family carers has documented the consider-
able burden attached to caring for persons with MND
[28,29]. Caregiver burden increases as patient function
declines [30-32]. Studies indicate that MND caregiver bur-
den can be alleviated by finding positive meaning [12,13]
and by supporting a sense of hope [14]. It can be inferred
that dignity therapy may impact hope and meaning, thereby
alleviating caregiver burden. In the alternative, whether this
intervention increases burden is a factor that also must
be considered when evaluating its overall impact.Secondary outcome measures for family carers
Secondary outcome measures used to assess the poten-
tial impact of dignity therapy on family carers includes
1) hopefulness, utilizing the Herth Hope Index [21]. The
HHI has been used successfully in studies with family
caregivers of terminally ill patients [33], and 2) anxiety
and depression, which will be measured with the Hos-
pital Anxiety and Depression Scale [34], an instrument
often used with family caregivers showing strong reli-
ability and validity. To assess the acceptability of dignity
therapy to family carers, a modified version of the dig-
nity therapy Family Feedback Questionnaire [17] is being
utilized to collect information on the views, experiences
and opinions of the family carers about the intervention.
MNDAWA contacts researcher with contact information for 
MND participant who has expressed an interest in the study
Continued Initial Session: 
Family Carer Demographic and Health 
Questionnaire
ALSFRS-R
Herth Hope Index
Zarit Burden Interview
Hospital Anxiety and Depression Scale
Continued Initial Session:
Patient Demographic and Health Questionnaire
ALSAQ-5 health assessment
Herth Hope Index
FACIT-sp
Patient Dignity Inventory
Dignity therapy session(s) 
(1-2 days later)
Review and Editing of Dignity therapy transcript 
(2-3 days later)
One week post-intervention
Patient Feedback Questionnaire
ALSAQ-5 health assessment 
Herth Hope Index
FACIT-sp
Patient Dignity Inventory
One week post-intervention
Family Carer Feedback Questionnaire
ALSFRS-R
Herth Hope Index
Zarit Burden Interview
Hospital Anxiety and Depression Scale
MND Participant
Initial Session:
Explain study and obtain consent
ALS-CBS
Family Carer
Initial Session:
Explain study and obtain consent, ALS-CBS
If family carer does not wish to participate, MND  
participant can proceed.
Return and ReviewDignity therapyTranscript
(2-3 days later)
Score of >10 on ALS-CBS, MND participant 
and family carer excluded from study 
Figure 1 Study Design Flow Chart.
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Demographic and health status information collected
from persons with MND will include disease specific
health-related quality of life utilizing the Amyotrophic
Lateral Sclerosis Assessment Questionnaire-5 [35], cogni-
tive behavioural functioning from the carer’s perspective
utilizing the ALS Cognitive Behavioral Screen [36], age,
gender, and health history.
Demographic and health status information collected
from family carers will include the level of disability of
the care recipient utilizing the Amyotrophic Lateral
Sclerosis Functional Rating Scale-R [37,38], cognitive be-
havioural functioning from the carer’s perspective utiliz-
ing the ALS Cognitive Behavioral Screen [36], age, gender,
relationship to the person with MND, caring hours per
day, employment status, and health history.Analysis
For summarizing purposes, descriptive statistics will
be obtained for demographic variables. To assess the
possible impact of the intervention on the psychosocial
and existential concerns of the participant and family
carer, pre and post intervention comparisons for each
outcome variable will be carried out using Wilcoxon’s
signed rank-sum tests, given that the main outcome
variable measured will not be normally distributed [16].
Spearman’s rank correlation coefficient will be calculated
to assess the possible correlation between variables of
interest. It is anticipated that there will be a post-
intervention improvement on all psychosocial measures
for both the participant and family carer after the dignity
therapy intervention. Open-ended responses in feedback
questionnaires will be coded and analysed using
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software package will be used for all analyses. A p value
less than 0.05 is considered to be statistically significant.
Discussion
Several studies, as well as MND practice guidelines, sug-
gest the need to develop and utilize interventions that
will support hopefulness, a sense of meaning, and dig-
nity in order to alleviate psychosocial and existential dis-
tress in persons with MND [7,8]. Despite this, very little
has been done to develop or implement such interven-
tions. In fact, an extensive literature search completed
for this study revealed there were no psychosocial inter-
ventions specifically designed or tailored to alleviate
existential distress and improve the quality of life of per-
sons with MND. This research will begin to fill this gap,
providing a possible solution to a concern about this
specific population, as well as continue to advance the
overall focus of alleviating psychosocial distress at the
end of life, an area of palliative care which has been
widely acknowledged as being in need of improvement.
This study will determine if dignity therapy is likely to
be effective in enhancing the end of life experience for
both people with MND and their family carers, if it is
acceptable to people with MND and their family carers,
and if it is feasible to offer the intervention to this popu-
lation. It will explore what allowances or modifications
might need to be made to deliver the intervention
to people who are sometimes unable to communicate
verbally. It will provide a preliminary examination of
how cognitive or neurobehavioral issues encountered in
persons with MND might affect the intervention, includ-
ing the completion and sharing of a generativity docu-
ment that reflects a true sense of the person with MND.
Finally, if the intervention is unsuccessful, this study will
determine what factors contributed to a negative out-
come, as well as any unexpected consequences to per-
sons with MND or their families.
This research has implications for psychological and
health care professionals who work with people with
motor neurone disease and other neurological disorders,
as well as those who work in palliative care settings.
Both are often called on to address the spiritual, existen-
tial and psychosocial needs in their patients. If dignity
therapy proves to be effective, it could be a relatively
brief and easy to administer intervention that could be
made available to people with MND. This study has the
potential to provide a precise intervention to ameliorate
psychosocial and existential distress, as well as improve
the quality of care provided to people with MND and
their family carers.
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